Pfizer to close even more doors in Ireland
Cork – Ireland is set to lose another 180 pharma jobs after pharmaceutical giant Pfizer announced it had failed to find a buyer for one of its five manufacturing facilities in the country. For the past 18 months, the company has been actively trying to sell the facility at Little Island as a going concern and retain employment there, but the sale fell through last month and the company says the facility will now close by the end of 2009. In a statement, the company said all possible avenues and opportunities to find a buyer have been exhausted, and that layoffs will begin on a phased basis from October. The company cites the abandonment of plans to produce a new anti-cholesterol drug called Torcebrapib at Ringaskiddy in 2006 as the major reason for closing one of its manufacturing units in the town in 2007 – with the loss of 65 jobs – and putting two of its facilities in Cork up for sale. Pfizer is one of Ireland’s largest pharmaceutical multinationals, and employs an Irish workforce of over 2,200. It was among the first to set up in Ireland, opening the main Ringaskiddy plant in Cork in 1972. In May, Pfizer said it was investing €190m, with the support of IDA Ireland, for the establishment of a biologics facility at Shanbally. The new plant will create about 100 new jobs over three years.